Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
Breast Cancer is the most prevalent cancer in the world with 4.4 million survivors up to 5 years following the diagnosis. 1 In the US alone approximately forty thousand women die annually of metastatic breast cancer (MBC). Despite many effective systemic treatment options approximately 50% of women...
Main Author: | Katherine H. Rak Tkaczuk |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2011-01-01
|
Series: | Breast Cancer: Basic and Clinical Research |
Online Access: | https://doi.org/10.4137/BCBCR.S5331 |
Similar Items
-
Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
by: Katherine H. Rak Tkaczuk
Published: (2011-01-01) -
Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
by: A S Kolbin, et al.
Published: (2017-01-01) -
Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
by: A S Kolbin, et al.
Published: (2018-03-01) -
Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case
by: E. V. Glazkova, et al.
Published: (2019-12-01) -
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
by: Massimo Cristofanilli
Published: (2012-01-01)